The emerging role of nimotuzumab in the treatment of non-small cell lung cancer by Boland, William & Bebb, Gwyn
© 2010 Boland and Bebb, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Biologics: Targets & Therapy 2010:4 289–298
Biologics: Targets & Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
289
REVIEW
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/BTT.S8617
The emerging role of nimotuzumab  
in the treatment of non-small cell lung cancer
William Boland1
Gwyn Bebb2,3
1Department of Anatomy and Cell 
Biology, McGill University, Montreal, 
Quebec, Canada; 2Tom Baker Cancer 
Centre, Calgary, Alberta, Canada; 
3University of Calgary, Calgary, 
Alberta, Canada
Correspondence: Gwyn Bebb 
Tom Baker Cancer Centre, University 
of Calgary, Translational Research 
Laboratory, 1331, 29th St NW, Calgary,  
T2N 4N2, Alberta, Canada 
Tel +1 403 521 3166 
Fax +1 403 283 1651 
Email gwyn.bebb@albertahealthservices.ca
Abstract:  Current  non-small  cell  lung  cancer  (NSCLC)  chemotherapy  and  radiotherapy 
regimens, although showing definite survival benefit, still leave patients with a disappointing 
15% 5-year overall survival rate. Because of the need to improve traditional outcomes, research 
has focused on identifying specific tumorigenic pathways that may serve as therapeutic targets. 
The most successful strategies to date are those aimed at the epidermal growth factor receptor 
(EGFR), which is found to be upregulated in 40%–80% of NSCLC. Several tyrosine kinase 
inhibitors and monoclonal antibodies (mAbs) have been developed that inhibit the EGFR 
receptor and have demonstrated clinical benefit in trials as single agents and in combination 
regimens. Here we discuss one such agent, the mAb nimotuzumab, the background of its 
development, its clinical experience in NSCLC thus far, and the rationale for expanding its use 
to other NSCLC treatment settings.
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Introduction
Lung cancer remains the primary source of cancer mortality worldwide and continues 
to increase in incidence in developing countries such as India and China.1,2 Within the 
United States and Canada, where incidence rates are dropping, it still accounts for 
more deaths than the next four leading malignancies combined and recently surpassed 
cerebral vascular disease as the number two killer overall.3–5 As a result, treating this 
disease, especially non-small cell lung cancer (NSCLC), which accounts for roughly 
85% of pulmonary malignancies,6 has become a major undertaking at medical centers 
around the world.
Standard treatment for NSCLC involves surgical resection, platinum-based 
chemotherapies, and radical or palliative radiotherapies, yet, prognoses have plateaued 
and, even for the earliest stages, remain relatively reserved.7 The five-year survival 
rate ranges from 49% for stage IA to 1% for stage IV disease,8 the majority of  deaths 
being caused by distal recurrence. Underpinning this poor outcome is the tendency to 
establish   diagnoses only at an advanced stage (in 70% of cases9) compounded by the 
comorbidities and decreased performance status of patients, who are often, or have been, 
chronic smokers. Given the limitations of traditional cytotoxic agents, novel targeted 
therapies became an exciting prospective field for NSCLC treatment in the late 90s and 
early 2000s. The most clinically relevant have been interventions aimed at the epidermal 
growth factor receptor (EGFR), including intracellularly acting tyrosine kinase inhibi-
tors (TKIs) and the extracellular-binding monoclonal   antibodies (mAbs).Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Targeting the EGFR
EGFR and NSCLC
EGFR (also HER1 or ErbB1) is a tyrosine kinase receptor and 
member of the ErbB family of transmembrane proteins that 
homodimerizes or heterodimerizes with another ErbB receptor 
under the influence of an extracellular agonist, usually epider-
mal growth factor (EGF) or transforming growth factor α.10 
Extracellular substrate binding brings the intracellular tyrosine 
kinase domains from the two receptors into close proximity, 
promoting intracellular autophosphorylation at specific resi-
dues and subsequent recruitment of downstream intermediate 
signaling proteins.11 As part of the Ras–mitogen-activated 
protein kinase, Akt and phosphotidylinositol 3-kinase (PI3 K)–
c-Jun N-terminal kinase signaling cascades, these downstream 
molecules are implicated in a plethora of cellular functions, 
such as proliferation, angiogenesis, antiapoptosis, and cell 
adhesion.12 Not surprisingly, changes to these pathways can 
elicit dramatic phenotypic transformation, including tumor 
development and evolution, by encouraging uncontrolled cell 
division, increased cell survival, tumor vascularization, tis-
sue invasion, and metastases.12–15 Accordingly, dysregulation 
of EGFR signaling has been associated with several human 
cancers, stimulating an early interest in it as a target for anti-
cancer agents.16,17 In NSCLC, aberrant EGFR signaling can be 
caused by an amplified gene copy number, found in 40%–80% 
of tumors, as well as the acquisition of somatic, constitutively 
activating mutations, the majority residing in exons 19 and 
21.17,18 Additionally, EGFR can become overstimulated by 
greater access to its ligands, which are often overproduced 
in tumors.17
By whichever route EGFR becomes dysfunctional, 
evidence suggests that increased signaling is generally 
associated with more undifferentiated and advanced disease 
and an overall worse prognosis in certain cancers.19 Moreover, 
EGFR overexpression has been associated with less effective 
chemotherapy and radiotherapy treatments.20,21 In the case of 
radiotherapy, studies show that tumors may upregulate EGFR 
in response to DNA damage, perhaps resulting in apoptosis 
avoidance by increasing EGFR-dependent survival cues.21 
Therefore, inhibitors of EGFR may have a potential synergistic 
effect with radiotherapy in addition to their inherent anti-
neoplastic nature. However, correlations between EGFR and 
disease status, prognosis, or response have been contentious, 
especially in NSCLC.19 Nevertheless, taken in   conjunction 
with the prevalence of EGFR upregulation in cancer and the 
importance of its downstream targets in tumorigenic   processes, 
inhibition of EGFR was seen as an exciting avenue of pursuit 
for NSCLC in the late 1990s.
Tyrosine kinase inhibitors
Gefitinib (Iressa), a TKI, was the first such inhibitor of 
EGFR to be approved for NSCLC and was followed quickly 
by erlotinib (Tarceva). These lipid-soluble molecules 
block the adenosine triphosphate-binding pocket of the 
EGFR tyrosine kinase domain, eliminating its ability to 
phosphorylate targets.22 They have proven to have a beneficial 
role in second-line treatment of metastatic NSCLC.23 Several 
independent studies demonstrate that the presence of EGFR-
activating mutations renders cells remarkably sensitive to 
these agents and underpins their clinical results,17,18,24,25 a 
phenomenon associated with nonsmoking Asian females.26 
Recent trials have confirmed the remarkable clinical activity 
of these agents in this setting, which as a result are now 
approved for use to treat metastatic NSCLC as single agents 
in the first-line setting of EGFR mutation–positive patients 
on several continents.27,28 Their role in combination with 
chemotherapy, however, remains unproven.29
Monoclonal antibodies
Coincident with the development of small molecular inhibi-
tors, mAbs targeting the extracellular component of EGFR 
and other signaling proteins thought to be associated with 
tumorigenesis, such as ErbB230 and vascular endothelial 
growth factor (VEGF),31 were developed. The antineoplastic 
EGFR-binding mAbs demonstrating anticancer potential 
thus far include cetuximab, panitumumab, zalutumumab, 
matuzumab, necitumumab, and nimotuzumab. It is believed 
they work by attaching to extracellular EGFR epitopes and 
sterically hindering the protein from taking on its optimum 
dimerization conformation or alternatively blocking EGFR 
interactions, in either case, inhibiting the formation of dimers 
and the subsequent activation of the receptor.32 However, it 
is also accepted that a profound immunomodulatory effect 
may be a component of their antitumor activity.33
Nimotuzumab
Preclinical data
Nimotuzumab was originally isolated as a mouse immuno-
globulin (Ig)G2a antibody known as R3, developed against 
placental-derived EGFR at the Molecular Immunology 
Center in Havana, Cuba.34 The R3 mAb was humanized 
to reduce its human immunogenicity and slow clearance 
from the body by grafting its complimentarity determining 
regions into a human IgG1 gene to create h-R3-nimotuzumab. 
Recreation of 3-specific murine amino acids (Serine 75, Thre-
onine (Thr) 76, and Thr 93) in the new antibody’s variable 
fraction preserved their anti-EGFR activity.34 Although a Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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crystallized protein model has yet to be completed, a likely 
  hypothesis for nimotuzumab binding to domain III of EGFR’s 
  extracellular region was developed by Talavera et al35 based 
on observed competition with cetuximab and computer 
simulations. The binding affinity (Kd) of nimotuzumab to 
EGFR is 4.5 × 10−8 m and is similar to EGF’s own affinity 
for EGFR,36,37 but is .10-fold less than competing mAbs, 
cetuximab, and panitumumab. Nimotuzumab can therefore 
be described as a humanized IgG1 antibody that attaches to 
the extracellular domain III of EGFR with a moderate affinity, 
blocking EGF binding and sterically hindering the receptor 
from exposing its dimerization motif.
Cultured cells expressing high levels of EGFR and 
treated with nimotuzumab show less receptor activation 
after being assayed with ligand.38 These in vitro results have 
been observed mainly in A431 cells, a vulvar epidermoid 
carcinoma cell line, characterized by high EGFR expression.39 
However, they have also been demonstrated in cells exhibiting 
wild-type and constitutively active EGFR, suggesting that 
nimotuzumab is equally successful at EGFR inhibition in 
both normal and mutant backgrounds.21 In vivo xenograft 
models have also confirmed this antitumor effect on A431 
cells in mice, an effect similar to that induced by cetuximab 
in the same model.38 More recent in vivo data demonstrates 
significant antitumor effect of nimotuzumab in xenografts 
utilizing the NSCLC cell lines H460, Ma-1, and H292.21 
This in vivo data hints strongly at an increasingly profound 
antitumor effect from nimotuzumab as the extent of EGFR 
expression rises from low in H460, to moderate in Ma-1, and 
to high in H292.21
Interestingly, in vitro cells bound by nimotuzumab do 
not exhibit an apoptotic phenotype.39 In vivo treated tumors, 
on the other hand, display a 5-fold increase in apoptotic 
activity generating a marked tumor regression within solid 
A431 severe combined immunodeficiency mice carcinomas.39 
This distinction between in vitro and in vivo response of 
nimotuzumab points toward a specific apoptotic mechanism 
unique to the in vivo environment. Crombet-Ramos et al39 
hypothesize that a decrease in angiogenesis is the major cause 
of in vivo tumor cell death by diminished VEGF production, 
a theory that has been supported by acquired resistance in 
cells constitutively producing VEGF.40 However, it should be 
pointed out that there are many other downstream targets that 
have not yet been ruled out as contributors to this effect.41 
Furthermore, a tumor-binding IgG1 antibody may augment 
any inherent antineoplastic effect by triggering the antibody-
dependent cell-mediated cyotoxicity immune mechanism to 
attack cancer cells independent of EGFR inhibition.38,42
Clinical experience
Solid tumors
Promising preclinical results with nimotuzumab led to its 
introduction into clinical trials in 2003, beginning with 
a Phase I Cuban trial.37 In this Phase I study, 12 patients 
were enrolled to receive a one-time dose of 50, 100, 200, 
or 400 mg of nimotuzumab, and, although 7 participants 
experienced mild or moderate adverse reactions, in   contrast 
to the experience with other anti-EGFR agents, none 
developed the classic anti-EGFR acneiform rash. There-
after, nimotuzumab was administered to more than 9,000 
recipients43 in over 30 Phase I and II trials (see Table 1) 
that confirm the lack of a severe skin reaction and other 
adverse reactions (reviewed44). Notably, a Canadian dose-
escalation Phase I study reported excellent tolerability of 
the drug in up to 800-mg weekly infusions, with only one 
dose-limiting toxicity of grade 3 fatigue being reported at 
the 100-mg level.45 Most other studies have mainly focused 
on head and neck squamous cell carcinomas (HNSCCs)46–49 
and brain malignancies50 (reviewed51), where nimotuzumab 
has shown an efficacy equal to or greater than comparable 
anti-EGFR mAbs.
The largest of the Phase II trials involving   nimotuzumab 
(BEST trial), completed at multiple centers in India, included 
92 patients with HNSCC who were   randomized to receive 
chemotherapy with nimotuzumab,   chemoradiotherapy 
with nimotuzumab, or chemotherapy and chemoradiation 
alone.52 This trial demonstrated a clinically significant 
30-month survival advantage with nimotuzumab over 
  combined chemotherapy and radiotherapy (69.57% 
with nimotuzumab vs 21.74% without nimotuzumab, 
P = 0.0011).53 Because of these and other successful 
trials (reviewed44), nimotuzumab has been approved for 
use in either HNSCCs or gliomas or both in 23 countries, 
  including China, India, and Brazil.54
Non-small cell lung cancer
Although an occasional NSCLC patient had been enrolled into 
dose-escalating Phase I trials up to this point, no clear signal 
of efficacy could be elicited based on such small numbers. On 
this basis, given the molecular rationale for targeting EGFR 
in NSCLCs, the early success of nimotuzumab in other solid 
tumors, and its benign side-effect profile, nimotuzumab use 
was expanded to a NSCLC population.
In the first such study (see Table 2), Bebb et al55 initiated 
a trial investigating the feasibility of adding the anti-EGFR 
mAb to palliative radiation in NSCLC patients of varying 
stages (IIB, III, and IV) deemed unsuitable for radical Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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therapy. Significantly, this cohort presented many of the 
classic challenges of NSCLC patient, being elderly and of 
less than ideal performance status (median age of 69 years 
and 5 of 18 patients were Eastern Cooperative Oncology 
Group performance status of 2). A similarly designed Korean 
trial by Choi et al56 documented almost identical results in a 
comparable, albeit, East Asian population. These two trials 
confirmed the minimal toxicity at each dose of nimotuzumab 
in combination with thoracic radiation, while also demon-
strating favorable results compared with historical controls57 
in a NSCLC setting (Table 2).
The overall impression gleaned from these studies is that 
nimotuzumab can be safely administered with doses of up to 
36 Gy of external beam ionizing radiation with minimal skin 
toxicity or esophagitis in an elderly NSCLC population. The 
fact that similar results were obtained in a North American 
and a Southeast Asian setting is notable. Unfortunately, the 
trials were not designed to assess the efficacy of nimotuzumab 
as a single agent, and although there were reports of response 
in tumors outside the radiation field, they remain anecdotal. 
These results are now set to be corroborated in randomized 
Phase II trials currently enrolling patients in Japan, South 
Africa, and Canada.
Brain metastases
The evolution of brain metastases from NSCLC heralds a 
grave prognosis, with only radiation and steroids being the 
mainstay of treatment. Given the excellent tolerability of nim-
otuzumab and its promising efficacy in primary brain tumors, 
assessing its efficacy in the setting of NSCLC metastatic to 
brain is logical. This was first done in a Phase II Cuban trial 
comparing nimotuzumab and radiation in NSCLC brain 
metastases with radiotherapy alone.58 A   preliminary report 
cites a disease control rate (DCR) of 91.6% (DCR = complete 
responses, partial responses, and stable disease) with a 
statistically significant improvement over irradiation only 
treated patients (P = 0.0039). Randomized Phase II trials 
designed to confirm these encouraging findings are also 
Table 1 Trials of nimotuzumab in solid tumors (excluding NSCLC)
Authors Phase Location No. of 
patients
Cancer 
stages
ORR DCR MST(mo) vs controls
Crombet et al37 
(2003)
I Cuba 12 Advanced 
epithelial
Winquist et al46 
(2002)
I Canada 17 HNSCC 87.5%
Crombet et al70 
(2004)
I/II Cuba 22 HNSCC 88%@200  
or 400 mg
8.6@50 
and 100 mg; 
44.3@200 
and 400 mg
Rojo et al47 
(2008)
I Spain 10 Advanced 
HNSCC
80%
Reddy et al48 
(2007)
II India 17 III or IVA, 
HNSCC
76% 90% increase 
ORR
Brade  
(2007)
I Canada 16 Advanced 
refractory 
CRC
43.8%
Crombet et al66 
(2006)
II Cuba 29 Gliomas 37.9%
Crombet 
(2008)
II/III Cuba 65 GB, AA 68.6% 37.2% increase 
DCR 
Bode  
(2007)
II Germany 46 Pediatric 
brain 
cancer
30.4% 45.5% 10 150% increase 
MST
Bode  
(2008)
III Germany 42 Pediatric 
brain 
cancer
Shah et al76 
(2009)
II Canada 61 Refractory 
CRC
50% 9.3
Reddy et al 
(2007)
II India 20 III or IVA 
HNSCC
100% 42.9% increase 
in ORR
Notes: ORR = complete responses + partial responses. DCR = ORR + stable disease. vs controls are comparisons of nimotuzumab to non-nimotuzumab controls.
Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; MST, median survival time; HNSCC, head and neck squamous 
cell carcinomas; CRC, colorectal cancer.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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now underway and recruiting in North America and South 
Africa.
The anti-EGFR side-effect profile
EGFR targeting TKIs and mAbs has been associated with 
several side effects, especially within organs with high 
levels of proliferation and EGFR expression, most notably 
the epidermis and intestinal lining. These include grade 3 
and 4 severe adverse events that can significantly impact a 
patient’s quality of life and result in a reduction or   cessation 
of continued treatment. The dermatological   reaction has 
been extensively described as an acneiform rash (although 
this term may be inaccurate)59 and is present in up to 90% 
of mAb-treated cases,60 38% of which are grade 3 or 4 
  reactions.61 Furthermore, experience in the head and neck 
cancer population suggests that the radiation-induced 
  dermatitis and mucositis may be exacerbated by the addition 
of an anti-EGFR monoclonal antibody.62–65
In contrast, these side effects are rare in cases of nimotu-
zumab use and are mainly limited to grade 1 or 2 adverse 
events.66 Most conspicuously, the typical grade 3 or 4 skin 
toxicity found in other anti-EGFR drugs has thus far remained 
virtually absent in nimotuzumab trials.44 In fact, when nimo-
tuzumab was tested for toxicity in the large mammal model 
Cercopithecus aethiops sabaeus (green monkeys), it was 
found to not display any dermatological side effects, even at 
doses 10 times the amount recommended for human use.36 
The cutaneaous manifestations of nimotuzumab treatment 
were investigated in the recently completed Korean Phase I 
trial,56 in which skin biopsies from a clinically normal skin 
area were collected before the first dose of nimotuzumab 
and after 2–8 weeks of treatment from 10 patients in the 
200 and 400 mg cohorts.   Histologically, the characteristic 
thinning of the stratum corneum and folliculitis induced 
by other EGFR inhibitors was not observed, whereas at 
the molecular level, nimotuzumab did not suppress EGFR 
  phosphorylation, receptor signaling, or keratinocyte pro-
liferation (Ki-67),56 echoing findings in a head and neck 
cancer trial.67   Nimotuzumab’s benign side-effect profile is 
not limited to the epidermis though, as it also includes the 
absence of severe hypomagnesemia and a lack of grade 3 or 
4 gastrointestinal side effects, commonly seen in this class 
of agents.68,69
The pharmacokinetic mechanism for why nimotuzumab 
seems to have similar antitumor activity to other EGFR-
targeted mAbs without the severe side effects could be its 
intermediate binding affinity. Decreased affinity to EGFR 
allows for an optimal dose of nimotuzumab that is below 
the toxic dose. Experimental mathematical models have 
predicted that for anti-EGFR mAbs to balance maximal 
tumor targeting with minimal normal cell toxicity, the 
binding affinity (Kd) should be in the range of 10−8–10−9 
M.70 Although nimotuzumab is within this range, cetuximab 
has a binding affinity 10-fold stronger. It has more recently 
been hypothesized by Tikhomirov et al71 that in contrast to 
other in-class mAbs, mainly cetuximab and panitumumab, 
nimotuzumab’s capacity to bind EGFR is heavily dictated 
by cell surface receptor density. This is attributed to the 
difference between monovalent and bivalent binding of 
nimotuzumab, which is transiently bound monovalently, 
and strongly bound bivalently to EGFR epitopes.71 In 
normal cells (eg, skin epithelial cells), EGFR expression is 
too low to cause nimotuzumab bivalent binding, therefore 
avoiding unwanted skin toxicities. Overexpressing tumor 
cells, on the other hand, will have enough receptor density 
for nimotuzumab to bind bivalently and robustly inhibit 
the EGFR.71,72 Whatever the reason, the absence of severe 
toxicity especially the skin rash could be a critical clinical 
Table 2 Nimotuzumab trials in NSCLC
Authors Phase Location No. of 
patients
Cancer Dosage ORR DCR MTP OST
Bebb et al55 I Canada 18 NSCLC 7@100 mg; 
6@200 mg; 
5@400 mg
66%a 94%a 5.4 mob 9.8 moc
Choi et al56 I Korea 15 NSCLC 5@100 mg; 
5@200 mg; 
5@400 mg
46.7%a 100%a 164 dd 298 de
Macias et al58f II Cuba 21 NSCLC brain 
metastases
200 mg 91.6%
Notes: a ORR and DCR within radiation field; b 95% CI, 0.9–9.9 months; c 95% CI, 6.5–13.1 months; d 95% CI, 26–302 days; e 95% CI, 199–397 days; f Based on preliminary 
results.
Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; DCR, disease control rate; MST, median survival time; OST, overall survival time; 
CI, confidence interval.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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bonus if nimotuzumab is shown to be efficacious in Phase 
II trials in NSCLC.
Nimotuzumab predictive markers
The paradigm of molecularly directed treatment, well defined 
in the world of leukemia and lymphoma, is also established in 
certain solid tumors such as breast cancer, where estrogen and 
progesterone receptor positivity has long-guided treatment 
and HER2 testing has helped direct the use of trastuzumab. 
Even in the colorectal cancer (CRC) world, several recent 
Phase III studies have shown that K-ras mutations preclude 
benefit from anti-EGFR mAb therapy in metastatic CRC.73–75 
The “realness” of this effect is supported by its demonstration 
in several line settings, with more than one anti-EGFR mAb, 
and when such an agent is used alone or in combination with 
chemotherapy. In a small Phase II trial of nimotuzumab with 
irinotecan in refractory CRC, there was a difference in overall 
survival between patients whose tumors were K-ras wild type 
compared with those with K-ras mutant tumors, suggesting 
that K-ras status may also be relevant in nimotuzumab use in 
CRC.76 However, this phenomenon does not seem to extend 
to NSCLC. Disappointingly, the role of K-ras as a predictive 
marker for the use of the anti-EGFR mAb cetuximab with 
platinum-based systemic treatment in stage-IV NSCLC was 
recently discredited in the FLEX study,77 which suggested 
that K-ras status is not a predictor of response to these agents 
in the treatment of metastatic NSCLC.78
Attempts at finding predictive markers specifically for 
nimotuzumab have to date not been forthcoming. Molecular 
determinants of response were investigated in both Phase I 
trials of nimotuzumab with palliative radiation in NSCLC. 
Markers investigated were EGFR status by immunohis-
tochemistry, EGFR gene copy number by fluorescence in 
situ hybridization analysis, and K-ras mutational status by 
sequencing. However, the paucity of high-quality biopsy 
material meant that only 10 of 18 patients in the Canadian 
study and 5 of 15 patients in the Korean study had tis-
sue available for molecular interrogation, and so, no clear 
molecular correlates could be established in either study. This 
is not unusual in lung cancer; a low proportion of analyz-
able samples is a conspicuous feature of all NSCLC trials 
that include molecular correlative studies in their design and 
sometimes leads to over interpretation of the significance of 
predictive molecular markers.79,80
Several explanations have been put forward to account 
for the difference in significance of K-ras mutations in 
NSCLC compared with CRC. An understudied factor may 
be the relative magnitude of the immune-modulatory effect 
of anti-EGFR mAbs in NSCLC compared with CRC. It has 
been demonstrated that the in vitro extent of cetuximab-
mediated lysis of HNSCC cells is influenced not only by 
EGFR expression and cetuximab concentration but also by 
FcγR polymorphism.81 FcγR polymorphisms have also been 
implicated in conferring different survival in CRC patients, 
even in those with K-ras mutation-bearing tumors.82,83 These 
studies strongly suggest that immune factors play a role in 
determining anti-EGFR mAb response irrespective of K-ras 
status. The relative magnitude of this effect in the efficacy 
of each anti-EGFR mAb is unknown. Future trials of these 
agents, including nimotuzumab, must incorporate attempts 
to better quantify this effect in NSCLC.
A second issue may be the very nature and role of K-ras 
mutations in NSCLC compared with CRC. Revisiting 
intriguing observations from the 1990s84 suggests that K-ras 
mutations differ in NSCLC compared with CRC in several 
ways, such as being less common (21% vs 39%), virtually 
absent in squamous cell tumors, more likely to be smoking 
associated (69% vs 38%), and more likely to be a transversion 
rather than a transition (3.0 vs 0.8). The relative importance 
of K-ras in each tumor must also be considered. It has been 
suggested that the PI3 K pathway assumes a greater impor-
tance in NSCLC than in CRC, thereby diminishing the role 
of K-ras in this setting.
Visions of nimotuzumab’s role  
in NSCLC management
As mentioned, a classic challenge of NSCLC management is 
that patients typically present in a disadvantaged condition. 
Median age at presentation is in the late 60’s and often comes 
with several comorbidities, a 33% probability of chronic 
obstructive pulmonary disease alone, and a performance 
status of 1 or more.85 Consequently, a large proportion of 
NSCLC patients is restricted in the degree of radical treat-
ment they can undergo, if any at all, not just by the stage of 
their cancer but by their overall health. Unpublished analysis 
at our own center suggests that only 23% of stage-IV NSCLC 
patients actually receive systemic treatment. In end-of-life 
circumstances where palliation and quality of life are the ulti-
mate objectives, a systemic therapeutic agent that can be used 
with minimal toxicity is obviously desirable. Nimotuzumab 
clearly fills these criteria but needs level I evidence based on 
randomized Phase III trials to support its use.
Adding a benign systemic treatment to palliative radia-
tion in individuals deemed too weak to receive standard 
cytotoxic therapy would also be quite attractive. The rela-
tionship between ionizing radiation and EGFR remains Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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intriguing. If, as proposed, radiation therapy increases EGFR 
cell surface concentrations and nimotuzumab activity is 
EGFR concentration dependent,21 then its activity should 
be more profound when used in conjunction with radio-
therapy.86 Additionally, in locally advanced cases where 
combined modality treatment results in long-term remission 
in only 15%–20%, the possibility of adding a well-tolerated, 
targeted systemic agent is welcomed. The presently enroll-
ing Phase II protocols in this setting will confirm whether 
nimotuzumab is as promising as preclinical and Phase I 
results suggest.
Although there have yet to be trials that test nimo-
tuzumab with chemotherapy in NSCLC, it also holds 
the potential to be a beneficial treatment paradigm. The 
possibility of achieving the same effect as cetuximab in 
the first-line setting in stage-IV NSCLC but with mini-
mal toxicity is of course alluring. At present, a Japanese 
study is enrolling patients for a Phase II examination of 
nimotuzumab with docetaxel in chemotherapy-refractory 
or resistance advanced NSCLC.
Unfortunately, as single agents, anti-EGFR therapeutics 
might be beneficial in the short-term, but inevitably tumors 
develop resistance to these drugs. It has been postulated that 
a significant mechanism of resistance is the utilization of 
alternate receptor pathways, such as the insulin-like growth 
factor-I receptor (IGF-IR) to bypass EGFR signaling block-
age or acquired mutations to molecular targets, like is seen 
in TKIs with EGFRvIII transmutation.87–89 Combined therapy 
against EGFR and potential resistance pathways has shown 
efficacy in some cases88 and therapies targeting more than one 
signaling receptor.90 Future NSCLC treatment may include 
the use of nimotuzumab to target the extracellular domain of 
EGFR in concert with TKIs inhibiting the cytosolic kinase 
and other targeted therapies acting against cancerogenic and 
resistance pathways, including VEGF and IGF-IR. However, 
this type of multimodal management strategy is only in 
the preclinical and early phases of clinical development, 
and unfortunately, some early studies record surprisingly 
detrimental effects.91,92 Obviously, more investigations are 
needed before this becomes an established paradigm for 
nimotuzumab in NSCLC management.
Summary
Nimotuzumab is a humanized anti-EGFR mAb that has 
demonstrated promising efficacy in the treatment of several 
EGFR-expressing solid tumors. Its tolerability in NSCLC 
has been demonstrated in two Phase I trials at doses of up 
to 400 mg in conjunction with external beam palliative 
radiation in both a Canadian and Korean population. Its 
utility in NSCLC will be demonstrated by ongoing Phase II 
trials. The most significant feature of nimotuzumab’s clinical 
experience to date is an intriguingly profound absence of the 
cutaneous anti-EGFR toxicity that is so characteristic of other 
anti-EGFR mAbs. This phenomenon has been attributed to 
a density-dependent binding to EGFR-expressing cells and 
may underpin a more optimal therapeutic window when 
nimotuzumab is used in conjunction with ionizing radiation. 
A politically unfavorable site of origin has hindered invest-
ment and the participation of US-based centers in clinical 
trials, but the recent initiation of manufacturing process in 
India may overcome this challenge. Meanwhile it is possible 
that nimotuzumab will find a niche in some markets where 
it will be promoted as a minimally toxic, less expensive 
anti-EGFR mAb. If the efficacy of this molecule compares 
favorably with other anti-EGFR mAbs in current clinical 
trials, then its lack of toxicity will make it a very attractive 
therapeutic agent indeed.
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